Personalized Medicine

Oncotarget

The cover for issue 29 of Oncotarget features Figure 2, "Categorisation of samples analysed," from Laes, et al.

- OncoDNA treatment recommendation followed in 60% of cases
- 93% of treatment decisions were made based on a holistic approach combining next generation sequencing (NGS) and multiple biomarker analysis provided by OncoDNA
- 27% of late-stage patients treated with OncoDNA-recommended therapies had overall survival less than 12 months, compared to a typical average of no more than six months
Gosselies, Belgium - April 17, 2018: OncoDNA ("OncoDNA or "the Company"), the healthcare technology company that collates and translates complex cancer biomarker data to make precision medicine a reality, is pleased to announce the publication of a study in the journal Oncotarget evaluating the utility of OncoDNA's comprehensive biomarker analysis and interpretation services in clinical settings.

The study, published online today and titled "The clinical impact of using complex molecular profiling strategies in routine oncology practice", found that combining advanced, comprehensive testing of cancer biomarkers with OncoDNA's proprietary cancer treatment knowledge database can enable oncologists to make better treatment decisions for their patients. This is because OncoDNA's testing combines immunohistochemistry, next generation sequencing (NGS), and other tests including inherited heart condition testing, DNA methylation, and microsatellite instability (MSI) testing, rather than the industry standard of NGS testing alone.

The study analysed samples from 1,057 late-stage and advanced grade cancer patients from over 30 different countries on four continents between January 2015 and January 2016 for whom at least one standard of care treatment had already failed. Samples were analysed either by the sequencing of a solid biopsy only - with either a hotspot panel or comprehensive panel including more than 400 genes - or the study of biomarkers determined by immunohistochemistry and other biomolecular tests, or a combination of both. In order to assess the utility of tumour profiling in clinical practice, the study also analysed the therapeutic decisions made by oncologists after receiving OncoDNA's tumour analysis and treatment recommendation.

Overall, OncoDNA's treatment recommendation was followed in 60.4% of cases and in 99% of the cases that did not follow the recommendation the cited reason was drug unavailability or cost, not clinical consideration. The vast majority of treatment decisions (93.4%) were made based on OncoDNA's combination of tests rather than NGS alone. This is a substantial increase on NGS testing alone, which will typically yield a treatment recommendation in only 30% of cases. For the cases in which OncoDNA's treatment recommendation was followed, 27% of patients had an overall survival of less than 12 months, a significant improvement for late-stage patients, who normally have a life expectancy of no more than six months.

Jean-Pol Detiffe, Chief Executive Officer of OncoDNA, said: "This dataset demonstrates the utility and power of OncoDNA's proprietary, living database and our holistic approach to genomic and molecular profiling. For oncologists, the study suggests our testing and analysis products could represent the best way to make informed therapeutic decisions in clinical practice. Not only were OncoDNA's recommendations followed in the majority of cases, but the study also suggests that our comprehensive testing and analyses could represent the best approach for obtaining useful molecular insight, while reducing physicians' exposure to irrelevant aberrations. As we continue to expand our business through Europe and beyond, these results will help raise awareness of the benefits of our product offering among oncologists and further the healthcare industry's ability to prescribe precision medicine."

Full text - https://www.oncotarget.com/article/24757/text/

Contact

OncoDNA+32 (0) 71 18 35 00

Jean-Pol Detiffe, CEO 
Jean-Francois Laes, CSO

Consilium Strategic Communications+44 (0)20 3709 5700

Amber Fennell, Sukaina Virji, Nicholas Brown, Hendrik Thys oncodna@consilium-comms.com

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/c/OncotargetYouTube/
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Author Insight: Unique Biomarker Analysis & Interpretation Platform in Clinical Decision-making

Sekisui XenoTech

Presenter: Dr. Brian Harvey, Emeritus Professor of Molecular Medicine at the Royal College of Surgeons in Ireland

Key concepts discussed in this webinar will include:
 - Background to the clinical use of dexamethasone in treating severe COVID-19
 - Novel molecular targets of dexamethasone in treating pulmonary edema in COVID-19
 - Molecular mechanisms of inhibitory effects of dexamethasone on ion channels
 - Gender disparity in inflammatory lung disease: COVID-19, Asthma and Cystic Fibrosis
 - Molecular mechanisms of sexual dimorphism in COVID-19 and CF
 - Sex hormone-related targets in COVID-19 and CF

Abstract:
In this webinar we will discuss novel molecular targets of the steroid dexamethasone and the steroid hormone estrogen in airway disease with a focus on Covid-19, asthma and cystic fibrosis.

Dexamethasone is a synthetic steroid commonly used in the treatment of inflammatory airway disease which has found a repurposed use in the clinical management of severe COVID-19 lung disease with great success in reducing mortality. The few clinical studies ascribe the therapeutic effects of dexamethasone to its anti-inflammatory actions, however, this does not explain the steroid action on reducing pulmonary edema per se and other targets may be involved. We have recently shown effects of dexamethasone to reduce secretion across human airway cell lines by inhibiting ion channels and these novel effects of the steroid will be discussed in detail.

A gender disparity has been observed since the first reports of COVID-19 appeared with more men than women suffering severe COVID19 disease and dying from it. The molecular mechanisms for this sexual dimorphism are still unknown although the evidence points to differences in estrogen hormone levels and estrogen receptor expression and their regulation of ACE2 receptor biology, after taking into account patients age and underlying comorbidities. We know that a ‘gender gap’ also exists in other lung diseases such as asthma and cystic fibrosis. Asthma has a higher prevalence in boys than in girls before puberty and a higher prevalence and severity in women than in men in adulthood. A similar trend is seen in cystic fibrosis with girls having an earlier onset of lung disease at puberty with more frequent pulmonary exacerbations and shorter life span than men in adulthood. Because of the complexity of these diseases, no single straightforward mechanism can explain the gender differences found in asthma and cystic fibrosis. In the latter half of the webinar we will focus on the influence of female sex hormones on CF pulmonary outcomes and summarise data from in vitro and in vivo experiments on how estrogen might modify airway clearance, immunity and bacterial infection in the CF airways. The potential for novel steroid hormone-related therapeutic interventions will also be discussed.

Download a copy of the slides: https://www.xenotech.com/wp-content/uploads/2021/11/Ion-Channel-Targets-of-Dexamethasone-and-Sex-Steroid-Hormones-in-Airway-Disease.pdf
https://www.xenotech.com/about/events/webinar-role-of-udp-glucuronosyltransferases-in-drug-metabolism-and-drug-drug-interactions/
Questions, comments and requests: https://www.xenotech.com/contact/
More information on our research services and test systems: https://www.xenotech.com
Other previously aired webinars: https://www.xenotech.com/access-adme-research-resources/resource-type/webinar/
Upcoming webinar notifications: https://www.xenotech.com/contact/newsletter-sign-up/
Request a webinar topic: https://www.xenotech.com/contact/webinar-seminar-request/

About the Presenter:
Dr. Brian Harvey is Emeritus Professor of Molecular Medicine at the Royal College of Surgeons in Ireland. He is also a Principal Investigator in the Ion Channel Group at the Centro di Estudios Cientificos, Chile, and Visiting Research Professor at the Sorbonne University, Paris. Brian holds a PhD in Physiology and Biophysics from the National University of Ireland and a DSc honoris causa from Michigan State University. His main research area is in cell and molecular endocrinology of rapid responses to steroid hormones and their regulation of ion channels on which he has published over 300 papers. He is a Chevalier of the French Order of Merit and Member of the Ordre des Palmes Academiques, and an elected fellow of the European Academy of Sciences and the Royal Irish Academy.

COVID-19 Drug Repurposing Webinar: Ion Channel Targets of Dexamethasone and Sex Steroid Hormones in Airway Disease

Aging (Aging-US)

Aging-US published this trending research paper as the cover for Issue 13, Volume 20, entitled, "Predicting physiological aging rates from a range of quantitative traits using machine learning” by researchers from the Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, MD; Department of Epidemiology, The Herbert Wertheim School of Public Health and Human Longevity Science, UC San Diego, La Jolla, CA; Department of Biostatistics, University of Michigan, Ann Arbor, MI; Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Monserrato, Italy; Geriatric Unit, Azienda Sanitaria di Firenze, Florence, Italy; Laboratory of Genetics and Genomics, National Institute on Aging, Baltimore, MD; ViQi, Inc., Santa Barbara, CA.

Abstract
It is widely thought that individuals age at different rates. A method that measures “physiological age” or physiological aging rate independent of chronological age could therefore help elucidate mechanisms of aging and inform an individual’s risk of morbidity and mortality. Here we present machine learning frameworks for inferring individual physiological age from a broad range of biochemical and physiological traits including blood phenotypes (e.g., high-density lipoprotein), cardiovascular functions (e.g., pulse wave velocity) and psychological traits (e.g., neuroticism) as main groups in two population cohorts SardiNIA (~6,100 participants) and InCHIANTI (~1,400 participants). The inferred physiological age was highly correlated with chronological age (R2 > 0.8). We further defined an individual’s physiological aging rate (PAR) as the ratio of the predicted physiological age to the chronological age. Notably, PAR was a significant predictor of survival, indicating an effect of aging rate on mortality. Our trait-based PAR was correlated with DNA methylation-based epigenetic aging score (r = 0.6), suggesting that both scores capture a common aging process. PAR was also substantially heritable (h2~0.3), and a subsequent genome-wide association study of PAR identified significant associations with two genetic loci, one of which is implicated in telomerase activity. Our findings support PAR as a proxy for an underlying whole-body aging mechanism. PAR may thus be useful to evaluate the efficacy of treatments that target aging-related deficits and controllable epidemiological factors.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.203660

DOI - https://doi.org/10.18632/aging.203660

Full Text - https://www.aging-us.com/article/203660/text

Correspondence to: Luigi Ferrucci email: ferruccilu@grc.nia.nih.gov, David Schlessinger email: schlessingerd@grc.nia.nih.gov, Ilya Goldberg email: ilya@viqi.org and Jun Ding email: jun.ding@nih.gov

Keywords: physiological aging rate, quantitative trait, machine learning, aging clock, mortality, personalized medicine

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ or connect with us on:

SoundCloud - https://soundcloud.com/aging-us​
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/agingus​
LinkedIn - https://www.linkedin.com/company/aging​
Pinterest - https://www.pinterest.com/AgingUS/

Aging-US is published by Impact Journals, LLC please visit http://www.ImpactJournals.com​​ or connect with @ImpactJrnls

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

Trending With Impact: Machine Learning Used to Estimate Physiological Age

Teach Me in 10

Science is a process, says Professor Yotam Ophir from the Department of Communication, University at Buffalo. This process is not finite. It involves a community of individuals coming together to continuously critique each other's research to further enhance, develop and update knowledge. In this Teach Me in 10, Professor Ophir explains the different narratives often used to communicate science and what impact these narratives can have on the general public's perception of scientific research. He also provides useful tips and tricks on how to communicate science effectively. You can read our recent interview published on Technology Networks [url][link]https://www.technologynetworks.com/tn/articles/scientific-storytelling-its-all-about-context-353303[/link][name]here[/name][/url]

How To Communicate Science Effectively With Professor Yotam Ophir

In this week’s Teach Me in 10, we are joined by Dr. Sarah Rosen, a postdoctoral researcher in the Klein lab at the Washington University in St. Louis. Rosen discusses her recent efforts into discovering why the mosquito-borne West Nile Virus affects men more severely than women. She will outline why sex differences in a type of immune cell in the brain, called microglia, might underlie these different outcomes.

Why More Men Die From West Nile Virus With Dr. Sarah Rosen

BioFluidix

The BioSpot CP is designed to realize complex laboratory tasks. Beside the standard BioSpot features like automated droplet volume calibration, aspiration and nozzle wash, nanoliter droplet dispensing, substrate ionizing and many more, the CP features an individual Z positioning per dispense channel. This allows for a multi-dimension addressability of any substrate. 
It's specific application is the parallelization of diagnostic tests in standard well plates and for combinatory chemistry (DoE). 
Get in touch to learn more about the BioSpot® workstation CP 600 at info@biofluidix.com.

BioSpot® workstation CP 600

Analytical Cannabis 

Speaking at the Analytical Cannabis Expo East Online 2020 back in October, Rob Dhoble, Managing Director at Havas ECS discussed a dual regulatory framework path to improve the needs of healthcare and selfcare. 

Abstract: Many Americans utilize OTC remedies in an attempt to fill the Rx affordability gap. In fact, 31% of surveyed adults report that they or a family member have relied upon home remedies or over-the-counter drugs instead of going to see a doctor, and 18% report not filling an Rx due to cost and taking an OTC product instead.
With large populations of individuals living with unmet and poorly met chronic medical needs, and the availability of relatively few FDA approved prescription cannabinoids, each narrowly labeled, and the widespread commercial availability of federally unregulated non-Rx cannabis products and non-intoxicating cannabinoids such as cannabigerol (CBG) and cannabidiol (CBD), our healthcare marketplace urgently requires a dual-path approach to ensure affordability, and market access to quality Rx and quality non-Rx cannabinoids for use under direction of medical professionals, and for use as non-Rx cannabinoids comprising ”selfcare”.   Specifically, a new “brief summary” non-Rx cannabinoid requirement is proposed, uniformly depicted on product packaging and within product advertising, to summarize the presence or absence of:
• independent laboratory assessed listing of product ingredients including CBD, THC, and other cannabinoids; linalool, myrcene, and other terpenes, inert ingredients, and the absence of contaminants
• identification of ingredients as being botanical, synthetic, or bio-synthetic 
• cGMP FDA compliance in manufacturing and packaging, including package expiration
• bioavailability data in how dose/serving size relates to absorption and blood levels

Rx and non-Rx Cannabinoids: A dual path regulatory framework for market access and product quality, to better support the needs of healthcare and selfcare.

CENTOGENE’s New and Improved Whole Exome Sequencing Service

It takes approx. 7 years to diagnose a patient with a rare disease. With NEW CentoXome®, we can turn those years into days – powered by our best-in-class insights based on superior technology, our extensive clinical experience, and wealth of genetic data in rare diseases.

NEW CentoXome - Turning Years Into Days

CELLSFORCELLS (C4C)

Cell-free therapy based on exosomes is witnessing a surge of published scientific papers, a rise of IP and registered clinicals trials, all driven by a swelling avidity among investors to support this transformative nanomedicine approach.

For cell-free treatment to become a reality, they need to overcome the many manufacturing hurdles posed by the large-scale production of purified exosomes.
Cells for Cells, a clinical-stage biotech company, has announced the publication of new data of its OxiumTMEXO cell culture media for increased exosome production in Frontiers in Biotechnology and Bioengineering, a specialized journal of the field. The company is part of REGENERO, the Chilean consortium for regenerative medicine supported by state funding (CORFO). In a head-to-head comparison, OxiumTMEXO outmatched the standard DMEM (starvation protocol) and a commercially available medium for exosome production. OxiumTMEXO allowed different type of cells, including the broadly used mesenchymal stem cells, to increase by 3-folds their particle production. The isolated exosomes expressed the typical pan markers while preserving their functionality both in vitro and in vivo.

Personalized Medicine

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.